首页 塞德斯疗法(usCLDX)-基本信息

塞德斯疗法(usCLDX)-基本信息

日报更新时间:04-17 11:30

周报更新时间:04-11 03:39

行情信息

今开价:24.09

最高价:24.17

成交量:310328.0

昨收价:23.56

最低价:22.94

最新价:23.55

行情图标
概要信息

中文名称:塞德斯疗法


英文名称:Celldex Therapeutics


行业:医疗


简介:Celldex Therapeutics, Inc.是一家生物制药公司,专注于几种免疫治疗技术治疗癌症和其他难以治疗的疾病的开发和商业化


电话:1-908-2007500


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Celldex是一家美国生物制药公司,其开发、生产并推出多种难治病的新疗法/新药物为人类健康服务。Celldex的PTI平台和单克隆抗体、抗体靶向疫苗以及免疫调节剂是一个互补组合,他用于不断优化组合,从而为多种疑难杂症开发特定的特效药。塞德斯医疗主要候选药物包括: CDX-110(Rindopepimut) - 一种针对胶质母细胞瘤的靶向免疫疗法产品,目前处于关键的第三阶段临床试验;此外,还在针对产品治疗胶质母细胞瘤复发进行研究,目前处于II期临床试验阶段。 CDX-011(Glembatumumab vedotin) - 一种靶向抗体 - 药物偶联疗法,目前对三阴性乳腺癌的治疗处于III期临床试验阶段;对转移性黑色素瘤的治疗处于II期临床试验阶段。 CDX-1127(Varlilumab) - 用于癌症适应症治疗的人单克隆抗体。 CDX-1401 - 靶向免疫治疗抗原呈递细胞的癌症适应症。 CDX-301 - 免疫细胞激活剂和树突状细胞的生长因子。 CDX-014 - 一个出自人的单克隆抗体-药物偶联靶向T细胞因子TIM-1,是一个被用在各种癌症治疗中分子,如:肾细胞癌和卵巢癌。目前,塞德斯医疗(Celldex Therapeutics)已与Medarex, Inc.、洛克菲勒大学、杜克大学脑肿瘤癌症中心、路德维格癌症研究所、Alteris Therapeutics, Inc.、南安普敦大学、安进公司、安进公司弗里蒙特(Amgen Fremont)以及西雅图遗传学公司(Seattle Genetics, Inc.)等公司、研究所及大学达成合作和许可协议,并与罗氏控股(Roche Holding)、施贵宝公司(Bristol-Myers Squibb Company)及赛瑞恩肿瘤药剂公司(Oncothyreon)公司等进行临床试验协作。

交易日期 交易人 职位 类型 交易份额 价格
2018-12-02 McMahon (Gerald) Director Sell 2824 0.30
2018-10-31 McMahon (Gerald) Director Sell 2888 0.31
2018-09-30 McMahon (Gerald) Director Sell 2888 0.45
2018-09-03 McMahon (Gerald) Director Sell 2813 0.50
2018-08-23 Marino (James J) Director Buy 40000 0.48
2018-07-31 McMahon (Gerald) Director Sell 2813 0.47
2018-07-01 McMahon (Gerald) Director Sell 2813 0.50
2018-06-14 Keler (Tibor) Officer Buy 16500 0.59
2018-05-31 McMahon (Gerald) Director Sell 2813 0.58
2018-04-30 McMahon (Gerald) Director Sell 2813 0.74
2018-04-01 McMahon (Gerald) Director Sell 3379 2.33
2018-02-28 McMahon (Gerald) Director Sell 3415 2.25
2018-01-31 McMahon (Gerald) Director Sell 3415 2.76
2018-01-01 McMahon (Gerald) Director Sell 3665 2.84
2017-11-30 McMahon (Gerald) Director Sell 3212 3.00
2017-10-31 McMahon (Gerald) Director Sell 3212 2.44
2017-10-01 McMahon (Gerald) Director Sell 3212 2.86
2017-08-31 McMahon (Gerald) Director Sell 3212 2.46
2017-07-31 McMahon (Gerald) Director Sell 2869 2.29

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Corp 28210 0.20% 28210 -- 2019-03-31
Acadian Asset Management LLC 147038 1.07% 147038 -- 2019-03-31
TSP Capital Management Group/LLC 156414 1.14% 156414 -- 2019-03-31
Dimensional Fund Advisors, Inc. 263839 1.92% 263839 -- 2019-03-31
Dimensional Fund Advisors LP 300144 2.18% -271767 -47.52% 2019-07-31
BlackRock Inc 303118 2.20% 303118 -- 2019-03-31
BlackRock Fund Advisors 4363452 2.40% -113536 -2.54% 2019-07-31
Vanguard Group Inc 488236 3.55% 488236 -- 2019-03-31
Renaissance Technologies Corp 545106 3.96% 545106 -- 2019-03-31
Vanguard Investments Australia Ltd 127392 0.93% -5859 -4.40% 2019-07-31
Bridgeway Capital Management, Inc 123700 0.90% 123700 -- 2019-03-31
Lake Street Risk Retention Group Inc 123700 0.90% 123700 -- 2019-03-31
Two Sigma Advisers, LLC 29897 0.22% 29897 -- 2019-03-31
Vassalluzzo Scott J 31000 0.23% 31000 -- 2019-03-31
State of New Jersey Common Pension Fd D 31666 0.23% 31666 -- 2019-03-31
Charles Schwab Investment Management Inc 440742 0.27% -229300 -34.22% 2019-07-31
Invesco Capital Management LLC 166419 0.37% 29095 21.19% 2019-07-31
Fidelity Management & Research Company 94955 0.69% -2036269 -95.54% 2019-07-31
D. E. Shaw & Co LP 105681 0.77% 105681 -- 2019-03-31
Geode Capital Management, LLC 108305 0.79% 108305 -- 2019-03-31
Susquehanna Financial Group, LLLP 23882 0.17% 23882 -- 2019-03-31
Susquehanna International Group, LLP 23882 0.17% 23882 -- 2019-03-31
Northern Trust Investments Inc 27518 0.19% -280267 -91.06% 2019-05-31
Northern Trust Investments N A 28210 0.20% 28210 -- 2019-03-31
Hand Benefits & Trust, a BPAS Co 19138 0.14% 1 0.01% 2019-05-31
Panagora Asset Management Inc 100357 0.05% 30668 44.01% 2018-12-31
Tekla Capital Management LLC 105800 0.05% -- -- 2019-04-30
State Street Global Advisors 8464 0.06% -- -- 2019-04-30
BlackRock 15054 0.11% -101916 -87.13% 2019-04-30
Exchange Traded Concepts, LLC 186218 0.09% -480839 -72.08% 2019-04-30
Mellon Investments Corporation 6336 0.05% -3853 -37.82% 2019-04-30
Legg Mason Partners Fund Advisor, LLC 5172 0.04% -- -- 2019-04-30
TOP Class Capital SL 70000 0.03% 20000 40.00% 2019-04-30
T. Rowe Price 3326 0.02% -49406 -93.69% 2019-04-30
DWS Investment S.A. 40999 0.02% -3 -0.01% 2019-04-30
Fidelity SelectCo, LLC 40992 0.02% -3558992 -98.86% 2019-04-30
State Street Global Advisors Ltd 37130 0.02% -43928 -54.19% 2019-04-30
GSA Capital Partners LLP 1270500 0.68% 630700 98.58% 2018-09-30
Two Sigma Investments LLC 1715216 0.92% 363616 26.90% 2018-09-30
Millennium Management LLC 1827248 0.98% -350702 -16.10% 2018-09-30
Deutsche Bank AG 1958077 1.05% -645168 -24.78% 2018-09-30
Meditor Group Ltd 6312700 3.38% -- -- 2018-09-30
Meditor Capital Management Limited 6312700 3.38% -- -- 2018-09-30
KLP Enterprises, LLC 6865000 3.68% -6 -- 2018-09-30
Connor Clark & Lunn Inv Mgmt Ltd 770060 0.42% -130125 -14.46% 2018-09-30
Goldman Sachs Group Inc 2003328 1.16% 1541666 333.94% 2018-06-30
BlackRock Institutional Trust Company NA 1807756 1.05% -1481125 -45.03% 2018-06-30
Goldman, Sachs & Co. 1945272 1.13% 1497976 334.90% 2018-06-30
Fidelity Management and Research Company 5968515 3.46% -1654237 -21.70% 2018-03-31
Ameriprise Financial Inc 7694417 4.46% 7193841 1437.11% 2018-03-31
Columbia Wanger Asset Management LLC 8471594 4.91% -1367419 -13.90% 2018-11-30
Oxford Asset Management, LLC 528874 0.37% 85419 19.26% 2018-03-31
Great Point Partners LLC 804483 0.51% 804483 -- 2018-06-30
Sunrise Partners LLC 640799 0.41% 629058 5357.79% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 219225 0.15% 44472 25.45% 2018-03-31
TIAA-CREF Investment Management LLC 421402 0.29% -230129 -35.32% 2018-03-31
Morgan Stanley & Co Inc 377407 0.26% 112883 42.67% 2018-03-31
Mellon Capital Management Corporation 302489 0.21% 7738 2.63% 2018-03-31
AllianceBernstein LP 460511 0.32% 12100 2.70% 2018-03-31
J.P. Morgan Investment Management Inc 963700 0.67% 963700 -- 2018-03-31
Citadel Advisors Llc 1214876 0.85% 475352 64.28% 2018-03-31
State Street Corp 2281379 1.59% 94176 4.31% 2018-03-31
Teachers Advisors Inc 1010601 0.70% 637786 171.07% 2018-03-31
State Of Wisconsin Investment Board 734014 0.51% -100986 -12.09% 2018-03-31
Numeric Investors LLC 660230 0.48% -25500 -3.72% 2017-12-31
Ascend Capital LLC 873995 0.63% -396828 -31.23% 2017-12-31
Artal Group S A 675000 0.51% -- -- 2017-09-30
FMR, Inc. 7785552 5.73% 7785552 -- 2017-11-30
Bogle Investment Management L P 996178 0.98% -926164 -48.18% 2016-09-30
RTW INVESTMENTS, LLC 1243164 1.23% -21063 -1.67% 2016-09-30
Frontier Capital Management CO Inc 1607068 1.59% -252704 -13.59% 2016-09-30
Franklin Advisers Inc 6270300 6.19% -6298 -0.10% 2016-09-30
The Vanguard Group 5405353 4.00% 151728259 -- 1999-11-30
BlackRock,Inc. 6304877 4.00% 176977897 0.10% 1999-11-30
Franklin Resources,Inc. 9570072 4.00% 268631921 0.10% 1999-11-30
FMRLLC 13438365 4.00% 377214906 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
DFA US Small Cap Portfolio 54754 0.40% -- -- 2019-05-31
Vanguard Extended Market Index Fund 155911 1.13% -- -- 2019-06-30
Vanguard Total Stock Market Index Fund 127392 0.93% -- -- 2019-06-30
Bridgeway Ultra Small Company Fund 123700 0.90% 123700 -- 2019-03-31
DFA US Core Equity II Fund 87898 0.64% -- -- 2019-05-31
DFA US Core Equity 1 Portfolio 74757 0.54% -- -- 2019-05-31
Schwab Total Stock Market Index Fund 8808 0.06% -- -- 2019-06-30
Invesco FTSE RAFI US 1500 Small-Mid ETF 42956 0.31% -- -- 2019-07-31
DFA US Targeted Value Portfolio 42912 0.31% -- -- 2019-05-31
iShares Micro-Cap ETF 36951 0.27% -- -- 2019-07-30
Fidelity 21055 0.15% -- -- 2019-06-30
DFA Tax Managed US Small Cap Portfolio 10678 0.08% -- -- 2019-06-30
Vanguard Instl Total Stock Market Idx Fd 10913 0.08% -- -- 2019-06-30
NT Ext Equity Market Index Fund - L 11284 0.08% -- -- 2019-06-30
BlackRock Extended Equity Market 12172 0.09% -17 -0.14% 2019-06-30
DFA US Vector Equity Fund 12846 0.09% -- -- 2019-06-30
DFA US Micro Cap Portfolio 16299 0.12% -- -- 2019-05-31
QS US Small Capitalization Equity CIF 19138 0.14% -- -- 2019-06-30
State Street U.S. Extended Market Index 8209 0.06% -- -- 2019-05-31
Schwab US Small-Cap ETF 431934 0.21% -- -- 2018-09-21
NT Extended Equity Market Idx Fund - NL 8025 0.06% -- -- 2019-03-31
NT Ext Equity Mkt Idx Fd - DC - NL 5324 0.04% -94 -1.73% 2019-03-31
Tekla World Healthcare Fund 105800 0.05% -- -- 2018-12-31
NT Ext Equity Mkt Fd - DC - NL 5324 0.04% -94 -1.73% 2019-03-31
QS US Small Capitalization Equity Fund 77587 0.04% -- -- 2018-12-31
Top Class Healthcare FI 70000 0.04% 20000 40.00% 2018-11-30
iShares Core S&P Total US Stock Mkt ETF 4386 0.04% 6 0.14% 2019-03-29
AST T. Rowe Price Growth Opps Port 3700 0.03% 3700 -- 2019-02-28
T. Rowe Price U.S. Equities Tr 49900 0.03% -- -- 2018-12-31
iShares Russell 2000 ETF 2806692 1.50% 34706 1.25% 2018-06-21
iShares Russell 2000 Value ETF 1482918 0.79% -2445 -0.16% 2018-06-21
Loncar Cancer Immunotherapy ETF 186218 0.10% -480839 -72.08% 2018-06-20
Invesco Russell 2000 Pure Value ETF 120281 0.06% 30544 34.04% 2018-06-24
Northern Small Cap Value Fund 175435 0.10% -145326 -45.31% 2018-09-30
Vanguard Balanced Index Fund 228670 0.13% -- -- 2018-11-30
iShares Nasdaq Biotechnology ETF 1787266 1.04% -3507 -0.20% 2018-11-30
Fidelity Advisor 865299 0.50% -- -- 2018-03-31
TIAA-CREF Quant Small-Cap Equity Fund 627300 0.36% -- -- 2018-04-30
Vanguard Health Care Index Fund 335822 0.19% 4619 1.39% 2018-10-31
AST Small Cap Value 355000 0.21% -- -- 2018-05-31
ESPA Stock Biotec 288000 0.17% -- -- 2018-03-31
Wanger USA 554441 0.32% -921000 -62.42% 2018-01-31
Columbia Acorn Fund 7655252 4.44% -- -- 2018-03-31
DFA US Core Equity 2 I 298513 0.18% -- -- 2018-07-31
Fidelity Spartan 215095 0.13% -- -- 2018-07-31
State Street Russell All Cap Index Fund Class I 40312 0.03% -- -- 2017-06-30
BlackRock Extended Equity Market K 181345 0.12% 4931 2.80% 2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls 195667 0.12% -- -- 2018-07-31
SSgA U.S. Total Market Index Fd Class I 24207 0.02% -1580 -6.13% 2017-12-31
Vanguard Health Care ETF 310353 0.19% 2499 0.81% 2018-07-31
Northern Small Cap Value 320761 0.20% -- -- 2018-06-30
Vanguard Total Stock Mkt Idx 3249146 2.00% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 1798645 1.11% 5 -- 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 336367 0.26% 8652 2.64% 2017-06-30
iShares Nasdaq Biotechnology 1842209 0.94% -3507 -0.19% 2018-09-12
DFA US Targeted Value I 795355 0.49% -- -- 2018-07-31
DFA US Micro Cap I 770480 0.47% -- -- 2018-07-31
DFA US Small Cap I 760034 0.47% -- -- 2018-07-31
DFA Tax-Managed US Targeted Value 357259 0.22% -- -- 2018-07-31
DFA US Core Equity 1 I 139559 0.09% -- -- 2018-06-30
Bridge Builder Small/Mid Cap Value 35756 0.02% 3941 12.39% 2018-03-31
JNL/Mellon Capital Healthcare Sector B 94153 0.07% -- -- 2018-03-31
CREF Stock R1 221223 0.15% -- -- 2018-04-30
LVIP SSgA Small Cap Index Std 113240 0.08% 33700 42.37% 2018-03-31
AXA 2000 Managed Volatility K 179604 0.13% -- -- 2018-05-31
Voya Russell Small Cap Index Port I 55256 0.04% -- -- 2018-03-31
BNY Mellon EB DL Mkt Completion 74081 0.05% -- -- 2018-03-31
QS Batterymarch US Sm Cap Eq I 77587 0.05% -- -- 2018-03-31
BNY Mellon EB DL Small Cap SIF 84290 0.06% 4646 5.83% 2018-03-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 323759 0.23% 2289 0.71% 2018-05-31
Northern Small Cap Index 76355 0.05% -- -- 2018-03-31
TIAA-CREF Small-Cap Equity Instl 627300 0.44% -- -- 2018-04-30
BlackRock Russell 2000 81665 0.06% -892 -1.08% 2018-03-31
BlackRock Russell 2500 201217 0.14% -7468 -3.58% 2018-03-31
iShares Russell 2000 Value 1482918 0.99% -2445 -0.16% 2018-06-21
Schwab Small Cap Index 229300 0.16% -- -- 2018-03-31
TIAA-CREF Small-Cap Blend Idx Inst 141834 0.10% -- -- 2018-03-31
VALIC Company II Small Cap Value 155700 0.11% -3600 -2.26% 2018-03-31
Columbia Acorn Z 7655252 5.34% -- -- 2018-03-31
Columbia Acorn USA Z 261901 0.19% -446419 -63.03% 2018-01-31
Vanguard Small Cap Index 1637271 1.16% 4189 0.26% 2018-02-28
Vanguard Small Cap Value Index Inv 502718 0.36% 1311 0.26% 2018-02-28
Vanguard Small Cap Growth Index Inv 454704 0.32% -172 -0.04% 2018-02-28
Columbia VP US Equities 2 461861 0.34% 59160 14.69% 2017-12-31
SPDR 2611353 2.71% -116661 -4.28% 2017-02-08
Franklin Small Cap Growth A 1719100 1.70% -- -- 2016-12-31
Franklin Biotechnology Discovery A 1265929 1.25% -- -- 2016-12-31
Franklin Small-Mid Cap Growth A 793900 0.78% -- -- 2016-12-31
Ohio National Bryton Growth 360299 0.36% -114500 -24.12% 2016-09-30
Oppenheimer Global Fund 4822392 4.90% 12410 0.30% 2015-09-30
Fidelity® Growth Company Fund 4467723 4.50% -48900 -1.10% 2015-09-30
Fidelity® Select Biotechnology Portfolio 3976706 4.00% -- -- 2015-09-30
Franklin Biotechnology Discovery 2020823 2.00% -61300 -2.90% 2015-07-31
First Trust NYSE Arca Biotech Fund 7326732 8.90% 24422 0.30% 2015-11-19
Franklin Small Cap Growth Fund 1795200 1.80% 325700 22.20% 2015-09-30
SPDR® S&P Biotech ETF 1532143 1.90% 10016 0.70% 2015-11-19
Franklin Biotechnology Discovery Fund 1343229 1.40% -- -- 2015-09-30
Fidelity® OTC Portfolio 1283885 1.30% -- -- 2015-09-30
Fidelity® Series Growth Company Fund 1206159 1.20% -- -- 2015-09-30
iShares Russell 2000 (AU) 1560684 1.90% -1968 -0.10% 2015-11-19

Herbert J. Conrad Herbert J. Conrad is a businessperson who founded Reliant Pharmaceuticals LLC and who has been at the helm of 7 different companies. Currently, he is Chairman for Matinas BioPharma Holdings, Inc. Mr. Conrad is also on the board of Celldex Therapeutics, Inc. In the past Herbert J. Conrad was Chairman at Matinas BioPharma, Inc., Chairman at GenVec, Inc., Chairman of Pharmasset, Inc., Chairman of Sapphire Therapeutics, Inc., Chairman for Bone Care International, Inc., President & Director at Roche Pharmaceuticals, Inc., President-Pharmaceuticals Division at F. Hoffmann-La Roche Ltd. and Director at Reliant Pharmaceuticals LLC. He received an undergraduate degree and a graduate degree from Arnold & Marie Schwartz College of Pharmacy & Health Science.
Ronald A. Pepin Ronald A. Pepin is on the board of Antyra, Inc. and Chief Business Officer & Senior Vice President at Celldex Therapeutics, Inc. In the past Dr. Pepin was Executive Director-External Science & Technology at Bristol-Myers Squibb Co. and Senior Vice President-Business Development at Medarex, Inc. (a subsidiary of Bristol-Myers Squibb Co.) and Vice President at Shire Pharmaceuticals, Inc. Dr. Pepin received an undergraduate degree from Tufts University and a doctorate from Georgetown University.
Richard Wright Richard Wright is Chief Commercial Officer & Senior Vice President at Celldex Therapeutics, Inc. He received an undergraduate degree from Rutgers State University of New Jersey, a graduate degree and a doctorate from the University of Medicine & Dentistry of New Jersey and an MBA from Columbia University.
Harry H. Penner Harry H. Penner is an entrepreneur and businessperson who founded 8 companies, which include: Marinus Pharmaceuticals, Inc., Melinta Subsidiary Corp. and RxGen, Inc. and who has been at the helm of 14 different companies. Currently, he is Executive Chairman of Prevention Pharmaceuticals, Inc. (which he founded), Executive Chairman at New Haven Pharmaceuticals, Inc. (which he founded in 2011), Chairman for QCDx LLC, Chairman & Chief Executive Officer for Nascent BioScience LLC and Chief Executive Officer & Director at Affinimark Technologies, Inc. (which he founded). Harry H. Penner is also on the board of Celldex Therapeutics, Inc., MAKScientific LLC, CaroGen Corp. and Omax Health, Inc. He previously held the position of Chairman at RxGen, Inc. (he founded the company in 2011), Chairman at RHEI Pharmaceuticals, Inc. (he founded the company), Executive Vice President of Novo Nordisk An and President at Novo Nordisk North America, Inc. (a subsidiary of Novo Nordisk A), Chairman at Celldex Therapeutics, Inc. (Old), Chairman & Chief Executive Officer of Nascent BioSciences Inc. (he founded the company in 2001), Vice Chairman, President & Chief Executive Officer at Neurogen Corp., Chairman of Connecticut Technology Council, Co-Chairman for Connecticut United for Research Excellence, Inc., Chairman for Connecticut Board of Governors for Higher Education, Director at Marinus Pharmaceuticals, Inc. and Director at Melinta Subsidiary Corp. Harry H. Penner received an undergraduate degree from the University of Virginia, a graduate degree from Fordham University and a graduate degree from New York University.
Harry H. Penner Harry H. Penner is an entrepreneur and businessperson who founded 8 companies, which include: Marinus Pharmaceuticals, Inc., Melinta Subsidiary Corp. and RxGen, Inc. and who has been at the helm of 14 different companies. Currently, he is Executive Chairman of Prevention Pharmaceuticals, Inc. (which he founded), Executive Chairman for New Haven Pharmaceuticals, Inc. (which he founded in 2011), Chairman at QCDx LLC, Chairman & Chief Executive Officer at Nascent BioScience LLC and Chief Executive Officer & Director at Affinimark Technologies, Inc. (which he founded). Mr. Penner is also on the board of Celldex Therapeutics, Inc., MAKScientific LLC, CaroGen Corp. and Omax Health, Inc. In the past Mr. Penner was Chairman at RxGen, Inc. (he founded the company in 2011), Chairman for RHEI Pharmaceuticals, Inc. (he founded the company), Executive Vice President at Novo Nordisk An and President of Novo Nordisk North America, Inc. (a subsidiary of Novo Nordisk A), Chairman at Celldex Therapeutics, Inc. (Old), Chairman & Chief Executive Officer of Nascent BioSciences Inc. (he founded the company in 2001), Vice Chairman, President & Chief Executive Officer at Neurogen Corp., Chairman for Connecticut Technology Council, Co-Chairman for Connecticut United for Research Excellence, Inc., Chairman at Connecticut Board of Governors for Higher Education, Director at Marinus Pharmaceuticals, Inc. and Director at Melinta Subsidiary Corp. Harry H. Penner received an undergraduate degree from the University of Virginia, a graduate degree from Fordham University and a graduate degree from New York University.
James J. Marino Mr. James J. Marino is an Independent Director at Celldex Therapeutics, Inc. and an Independent Director at Onconova Therapeutics, Inc. He is on the Board of Directors at Celldex Therapeutics, Inc., Onconova Therapeutics, Inc., Wake Forest Baptist Medical Center and Wake Forest University. Mr. Marino was previously employed as a Co-Founder by BioNJ, Inc. and a Partner by Dechert LLP. He also served on the board at Pharmacopeia LLC, Pharmacopeia, Inc. /Old/ and Robert Wood Johnson University Hospital, Inc. He received his undergraduate degree from Rutgers State University of New Jersey, a graduate degree from Rutgers State University of New Jersey and an MBA from Rutgers State University of New Jersey.
Tibor Keler Founder of Celldex Therapeutics, Inc., Tibor Keler currently is Chief Scientific Officer, VP-Research & Discovery at Celldex Research Corp. and Chief Scientific Officer & Executive VP at Celldex Therapeutics, Inc. In his past career Dr. Keler was Chief Scientific Officer & Senior Vice President at AVANT Immunotherapeutics, Inc., Chief Scientific Officer, VP-Research & Discovery at Celldex Therapeutics, Inc. (Old) and Director-Preclinical Development at Medarex, Inc. Dr. Keler received a doctorate from the University of Pennsylvania and an undergraduate degree and a graduate degree from Drexel University.
Karen Lipton Shoos Karen Lipton Shoos is Chairman at Celldex Therapeutics, Inc. In her past career Ms. Shoos held the position of Chief Executive Officer of American Association of Blood Banks and Senior Vice President-Biomedical Services at The American National Red Cross. She received an undergraduate degree from Yale University and a graduate degree from Case Western Reserve University.
Anthony S. Marucci Anthony S. Marucci is a businessperson who founded Celldex Therapeutics, Inc. and who has been at the helm of 5 different companies. Currently, Mr. Marucci is President, Chief Executive Officer & Director at Celldex Therapeutics, Inc., President of CuraGen Corp. (a subsidiary of Celldex Therapeutics, Inc.) and President, CEO, CFO, Secretary, Treasurer & VP at Celldex Research Corp. He is also on the board of BioNJ, Inc., Celldex Therapeutics Ltd. and College of Business & Public Management. In the past Anthony S. Marucci occupied the position of Interim President & Chief Executive Officer at AVANT Immunotherapeutics, Inc., Treasurer & Acting Chief Executive Officer at Celldex Therapeutics, Inc. (Old) and Treasurer for Medarex, Inc. Mr. Marucci received an MBA from Columbia University and an undergraduate degree from Kean University.
Tibor Keler Founder of Celldex Therapeutics, Inc., Tibor Keler currently is Chief Scientific Officer, VP-Research & Discovery at Celldex Research Corp. and Chief Scientific Officer & Executive VP at Celldex Therapeutics, Inc. In his past career Dr. Keler was Chief Scientific Officer & Senior Vice President at AVANT Immunotherapeutics, Inc., Chief Scientific Officer, VP-Research & Discovery at Celldex Therapeutics, Inc. (Old) and Director-Preclinical Development at Medarex, Inc. Dr. Keler received a doctorate from the University of Pennsylvania and an undergraduate degree and a graduate degree from Drexel University.
Tibor Keler Founder of Celldex Therapeutics, Inc., Tibor Keler currently is Chief Scientific Officer, VP-Research & Discovery at Celldex Research Corp. and Chief Scientific Officer & Executive VP at Celldex Therapeutics, Inc. In his past career Dr. Keler was Chief Scientific Officer & Senior Vice President at AVANT Immunotherapeutics, Inc., Chief Scientific Officer, VP-Research & Discovery at Celldex Therapeutics, Inc. (Old) and Director-Preclinical Development at Medarex, Inc. Dr. Keler received a doctorate from the University of Pennsylvania and an undergraduate degree and a graduate degree from Drexel University.
Sarah Boylan Cavanaugh Presently, Sarah Boylan Cavanaugh occupies the position of Senior VP-Corporate Affairs & Administration at Celldex Therapeutics, Inc. In her past career she held the position of Vice President for MacDougall Biomedical Communications, Inc., Director-Corporate Communications at Point Therapeutics, Inc., Director-Corporate Communications at Fallon Community Health Plan, Inc. and Marketing Director at American Cancer Society, Inc. Ms. Cavanaugh received an undergraduate degree from the University of New Hampshire.
Elizabeth Crowley Elizabeth Crowley is on the board of Horizons for Homeless Children, Inc. and Chief Product Development Officer & Senior VP at Celldex Therapeutics, Inc. Ms. Crowley previously occupied the position of Vice President-Development Operations at CuraGen Corp. She received an undergraduate degree from Boston College.
Keith L. Brownlie Keith L. Brownlie is on the board of Soligenix, Inc., Celldex Therapeutics, Inc. and Phio Pharmaceuticals Corp. and Member of The American Institute of Certified Public Accountants. He previously was Audit Partner at Ernst & Young LLP. He received an undergraduate degree from Lehigh University.
Richard Wright Richard Wright is Chief Commercial Officer & Senior Vice President at Celldex Therapeutics, Inc. Dr. Wright received an undergraduate degree from Rutgers State University of New Jersey, a graduate degree and a doctorate from the University of Medicine & Dentistry of New Jersey and an MBA from Columbia University.
Richard Wright Richard Wright is Chief Commercial Officer & Senior Vice President at Celldex Therapeutics, Inc. Dr. Wright received an undergraduate degree from Rutgers State University of New Jersey, a graduate degree and a doctorate from the University of Medicine & Dentistry of New Jersey and an MBA from Columbia University.
Diane C. Young Diane C. Young is on the board of The Valerie Fund. In her past career she occupied the position of Chief Medical Officer & Vice President at GTx, Inc. and Vice President-Global Development at R.W. Johnson Pharmaceutical Research Institute. Diane C. Young received a doctorate from Harvard Medical School and an undergraduate degree from Harvard University.
Sam Martin Presently, Sam Martin is CFO, Secretary, Treasurer & Senior Vice President at Celldex Therapeutics, Inc. In the past Mr. Martin was Director-Finance & Corporate Compliance at Alseres Pharmaceuticals, Inc. and Audit Manager at Ernst & Young LLP. He received an MBA from Boston University and an undergraduate degree from Skidmore College.
Margo Heath Chiozzi Margo Heath Chiozzi is Senior Vice President-Regulatory Affairs at Celldex Therapeutics, Inc. In her past career she was Medical Director at Abbott Laboratories, Vice President at Bristol-Myers Squibb Co., Director-HIV Research Clinical at The Queen's Medical Center, Director-Women's Immunology Clinical at Kapiolani Medical Center for Women & Children and Assistant Professor at John A. Burns School of Medicine. She received an undergraduate degree and a doctorate from the University of Utah.
Margo Heath Chiozzi Margo Heath Chiozzi is Senior Vice President-Regulatory Affairs at Celldex Therapeutics, Inc. In her past career she was Medical Director at Abbott Laboratories, Vice President at Bristol-Myers Squibb Co., Director-HIV Research Clinical at The Queen's Medical Center, Director-Women's Immunology Clinical at Kapiolani Medical Center for Women & Children and Assistant Professor at John A. Burns School of Medicine. She received an undergraduate degree and a doctorate from the University of Utah.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐